| 摘要 |
<p>The invention relates to a pharmaceutical composition with sustained trimetazidine release intended to be used in the treatment of angor pectoris, coronary disorders and dizziness of vascular origin and to a process for preparing the same. According to the invention, the composition consists of a neutral core, an internal phase comprising trimetazidine and a binder, an external layer comprising a retarding agent, an anti-agglomeration agent and a plasticizer. The process claimed by the invention consists in successively coating the neutral core with trimetazidine and binder, then with a retarding agent, a plasticizer and an anti-agglomeration agent, after which the resulting mini granules are conditioned to obtain the trimetazidine dissolution profile ensuring a therapeutically-effective plasmatic concentration.</p> |
